Gazing into the future: Parkinson's disease gene therapeutics to modify natural history

Experimental Neurology

Volumn 209, Issue 1, 2008, Pages 101-113

  Maguire Zeiss, Kathleen A ^a   Mhyre, Timothy R ^a   Federoff, Howard J ^b  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID DECARBOXYLASE; BIOLOGICAL MARKER; DOPAMINE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; INTERLEUKIN 10; NONSTEROID ANTIINFLAMMATORY AGENT; VASOACTIVE INTESTINAL POLYPEPTIDE;

ARTICLE; BRAIN; CELL LOSS; DOPAMINERGIC NERVE CELL; EARLY INTERVENTION; GENE THERAPY; HISTORY; HUMAN; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; GENE THERAPY; HUMANS; INFLAMMATION; NERVE DEGENERATION; NERVOUS SYSTEM; PARKINSON DISEASE;

EID: 37549052950     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2007.09.030     Document Type: Article

References (212)

1. Alexander H.K., Booy E.P., Xiao W., Ezzati P., Baust H., and Los M. Selected technologies to control genes and their products for experimental and clinical purposes. Arch. Immunol. Ther. Exp. (Warsz) 55 (2007) 139-149
2. Anton R., Kordower J.H., Maidment N.T., Manaster J.S., Kane D.J., Rabizadeh S., Schueller S.B., Yang J., Edwards R.H., et al. Neural-targeted gene therapy for rodent and primate hemiparkinsonism. Exp. Neurol. 127 (1994) 207-218
3. Arimoto T., Choi D.Y., Lu X., Liu M., Nguyen X.V., Zheng N., Stewart C.A., Kim H.C., and Bing G. Interleukin-10 protects against inflammation-mediated degeneration of dopaminergic neurons in substantia nigra. Neurobiol. Aging 28 (2006) 894-906
4. Asheuer M., Pflumio F., Benhamida S., Dubart-Kupperschmitt A., Fouquet F., Imai Y., Aubourg P., and Cartier N. Human CD34+cells differentiate into microglia and express recombinant therapeutic protein. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 3557-3562
5. Azizi S.A., Stokes D., Augelli B.J., DiGirolamo C., and Prockop D.J. Engraftment and migration of human bone marrow stromal cells implanted in the brains of albino rats-similarities to astrocyte grafts. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 3908-3913
6. Azzouz M., Martin-Rendon E., Barber R.D., Mitrophanous K.A., Carter E.E., Rohll J.B., Kingsman S.M., Kingsman A.J., and Mazarakis N.D. Multicistronic lentiviral vector-mediated striatal gene transfer of aromatic l-amino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase I induces sustained transgene expression, dopamine production, and functional improvement in a rat model of Parkinson's disease. J. Neurosci. 22 (2002) 10302-10312
7. Baatile J., Langbein W.E., Weaver F., Maloney C., and Jost M.B. Effect of exercise on perceived quality of life of individuals with Parkinson's disease. J. Rehabil. Res. Dev. 37 (2000) 529-534
8. Baba Y., Kuroiwa A., Uitti R.J., Wszolek Z.K., and Yamada T. Alterations of T-lymphocyte populations in Parkinson disease. Parkinsonism Relat. Disord. 11 (2005) 493-498
9. Banati R.B., Daniel S.E., and Blunt S.B. Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease. Mov. Disord. 13 (1998) 221-227
10. Bankiewicz K.S., Leff S.E., Nagy D., Jungles S., Rokovich J., Spratt K., Cohen L., Libonati M., Snyder R.O., and Mandel R.J. Practical aspects of the development of ex vivo and in vivo gene therapy for Parkinson's disease. Exp. Neurol. 144 (1997) 147-156
11. Bankiewicz K.S., Bringas J.R., McLaughlin W., Pivirotto P., Hundal R., Yang B., Emborg M.E., and Nagy D. Application of gene therapy for Parkinson's disease: nonhuman primate experience. Adv. Pharmacol. 42 (1998) 801-806
12. Bankiewicz K.S., Eberling J.L., Kohutnicka M., Jagust W., Pivirotto P., Bringas J., Cunningham J., Budinger T.F., and Harvey-White J. Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp. Neurol. 164 (2000) 2-14
13. Barbanti P., Fabbrini G., Ricci A., Cerbo R., Bronzetti E., Caronti B., Calderaro C., Felici L., Stocchi F., Meco G., Amenta F., and Lenzi G.L. Increased expression of dopamine receptors on lymphocytes in Parkinson's disease. Mov. Disord. 14 (1999) 764-771
14. Barbanti P., Fabbrini G., Ricci A., Bruno G., Cerbo R., Bronzetti E., Amenta F., and Luigi Lenzi G. Reduced density of dopamine D2-like receptors on peripheral blood lymphocytes in Alzheimer's disease. Mech. Ageing Dev. 120 (2000) 65-75
15. Barkats M., Bilang-Bleuel A., Buc-Caron M.H., Castel-Barthe M.N., Corti O., Finiels F., Horellou P., Revah F., Sabate O., and Mallet J. Adenovirus in the brain: recent advances of gene therapy for neurodegenerative diseases. Prog. Neurobiol. 55 (1998) 333-341
16. Barlow B.K., Cory-Slechta D.A., Richfield E.K., and Thiruchelvam M. The gestational environment and Parkinson's disease: evidence for neurodevelopmental origins of a neurodegenerative disorder. Reprod. Toxicol. 23 (2007) 457-470
17. Bas J., Calopa M., Mestre M., Mollevi D.G., Cutillas B., Ambrosio S., and Buendia E. Lymphocyte populations in Parkinson's disease and in rat models of parkinsonism. J. Neuroimmunol. 113 (2001) 146-152
18. Bechmann I., Goldmann J., Kovac A.D., Kwidzinski E., Simburger E., Naftolin F., Dirnagl U., Nitsch R., and Priller J. Circulating monocytic cells infiltrate layers of anterograde axonal degeneration where they transform into microglia. Faseb J. 19 (2005) 647-649
19. Bensadoun J.C., Deglon N., Tseng J.L., Ridet J.L., Zurn A.D., and Aebischer P. Lentiviral vectors as a gene delivery system in the mouse midbrain: cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF. Exp. Neurol. 164 (2000) 15-24
20. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., and Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3 (2000) 1301-1306
21. Biffi A., Capotondo A., Fasano S., del Carro U., Marchesini S., Azuma H., Malaguti M.C., Amadio S., Brambilla R., Grompe M., Bordignon C., Quattrini A., and Naldini L. Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice. J. Clin. Invest. 116 (2006) 3070-3082
22. Blandini F., Cosentino M., Mangiagalli A., Marino F., Samuele A., Rasini E., Fancellu R., Tassorelli C., Pacchetti C., Martignoni E., Riboldazzi G., Calandrella D., Lecchini S., Frigo G., and Nappi G. Modifications of apoptosis-related protein levels in lymphocytes of patients with Parkinson's disease. The effect of dopaminergic treatment. J. Neural Transm. 111 (2004) 1017-1030
23. Blandini F., Sinforiani E., Pacchetti C., Samuele A., Bazzini E., Zangaglia R., Nappi G., and Martignoni E. Peripheral proteasome and caspase activity in Parkinson disease and Alzheimer disease. Neurology 66 (2006) 529-534
24. Bongioanni P., Castagna M., Maltinti S., Boccardi B., and Dadone F. T-lymphocyte tumor necrosis factor-alpha receptor binding in patients with Parkinson's disease. J. Neurol. Sci. 149 (1997) 41-45
25. Bongioanni P., Mondino C., Borgna M., Boccardi B., Sposito R., and Castagna M. T-lymphocyte immuno-interferon binding in parkinsonian patients. J. Neural Transm. 104 (1997) 199-207
26. Borta A., and Hoglinger G.U. Dopamine and adult neurogenesis. J. Neurochem. 100 (2007) 587-595
27. Bowers W.J., Howard D.F., and Federoff H.J. Gene therapeutic strategies for neuroprotection: implications for Parkinson's disease. Exp. Neurol. 144 (1997) 58-68
28. Bowers W.J., Maguire-Zeiss K.A., Harvey B.K., and Federoff H.J. Gene therapeutic approaches to the treatment of Parkinson's disease. Clin. Neurosci. Res. 1 (2001) 483-495
29. Brenneman D.E., Glazner G., Hill J.M., Hauser J., Davidson A., and Gozes I. VIP neurotrophism in the central nervous system: multiple effectors and identification of a femtomolar-acting neuroprotective peptide. Ann. N. Y. Acad. Sci. 865 (1998) 207-212
30. Brooks A.I., Chadwick C.A., Gelbard H.A., Cory-Slechta D.A., and Federoff H.J. Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss. Brain Res. 823 (1999) 1-10
31. Cadet P., Zhu W., Mantione K., Rymer M., Dardik I., Reisman S., Hagberg S., and Stefano G.B. Cyclic exercise induces anti-inflammatory signal molecule increases in the plasma of Parkinson's patients. Int. J. Mol. Med. 12 (2003) 485-492
32. Casarejos M.J., Menendez J., Solano R.M., Rodriguez-Navarro J.A., Garcia de Yebenes J., and Mena M.A. Susceptibility to rotenone is increased in neurons from parkin null mice and is reduced by minocycline. J. Neurochem. 97 (2006) 934-946
33. Castelo-Branco G., Sousa K.M., Bryja V., Pinto L., Wagner J., and Arenas E. Ventral midbrain glia express region-specific transcription factors and regulate dopaminergic neurogenesis through Wnt-5a secretion. Mol. Cell. Neurosci. 31 (2006) 251-262
34. Chen H., Zhang S.M., Hernan M.A., Schwarzschild M.A., Willett W.C., Colditz G.A., Speizer F.E., and Ascherio A. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch. Neurol. 60 (2003) 1059-1064
35. Chen H., Jacobs E., Schwarzschild M.A., McCullough M.L., Calle E.E., Thun M.J., and Ascherio A. Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann. Neurol. 58 (2005) 963-967
36. Choi-Lundberg D.L., Lin Q., Chang Y.N., Chiang Y.L., Hay C.M., Mohajeri H., Davidson B.L., and Bohn M.C. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 275 (1997) 838-841
37. Choi-Lundberg D.L., Lin Q., Schallert T., Crippens D., Davidson B.L., Chang Y.N., Chiang Y.L., Qian J., Bardwaj L., and Bohn M.C. Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor. Exp. Neurol. 154 (1998) 261-275
38. Chung C.Y., Seo H., Sonntag K.C., Brooks A., Lin L., and Isacson O. Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection. Hum. Mol. Genet. 14 (2005) 1709-1725
39. Colby D.W., Chu Y., Cassady J.P., Duennwald M., Zazulak H., Webster J.M., Messer A., Lindquist S., Ingram V.M., and Wittrup K.D. Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 17616-17621
40. Connor B., Kozlowski D.A., Schallert T., Tillerson J.L., Davidson B.L., and Bohn M.C. Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat. Gene Ther. 6 (1999) 1936-1951
41. Coon S., Stark A., Peterson E., Gloi A., Kortsha G., Pounds J., Chettle D., and Gorell J. Whole-body lifetime occupational lead exposure and risk of Parkinson's disease. Environ. Health Perspect. 114 (2006) 1872-1876
42. Crizzle A.M., and Newhouse I.J. Is physical exercise beneficial for persons with Parkinson's disease?. Clin. J. Sport Med. 16 (2006) 422-425
43. Cucchiarini M., Ren X.L., Perides G., and Terwilliger E.F. Selective gene expression in brain microglia mediated via adeno-associated virus type 2 and type 5 vectors. Gene Ther. 10 (2003) 657-667
44. Cunningham L.A., and Su C. Astrocyte delivery of glial cell line-derived neurotrophic factor in a mouse model of Parkinson's disease. Exp. Neurol. 174 (2002) 230-242
45. Czlonkowska A., Kohutnicka M., Kurkowska-Jastrzebska I., and Czlonkowski A. Microglial reaction in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced Parkinson's disease mice model. Neurodegeneration 5 (1996) 137-143
46. Dawson T.M., and Dawson V.L. Rare genetic mutations shed light on the pathogenesis of Parkinson disease. J. Clin. Invest. 111 (2003) 145-151
47. Deguil J., Jailloux D., Page G., Fauconneau B., Houeto J.L., Philippe M., Muller J.M., and Pain S. Neuroprotective effects of pituitary adenylate cyclase-activating polypeptide (PACAP) in MPP(+)-induced alteration of translational control in Neuro-2a neuroblastoma cells. J. Neurosci. Res. 85 (2007) 2017-2025
48. Dejda A., Sokolowska P., and Nowak J.Z. Neuroprotective potential of three neuropeptides PACAP, VIP and PHI. Pharmacol Rep. 57 (2005) 307-320
49. Delgado M., and Ganea D. Vasoactive intestinal peptide prevents activated microglia-induced neurodegeneration under inflammatory conditions: potential therapeutic role in brain trauma. Faseb J. 17 (2003) 1922-1924
50. Delgado M., and Ganea D. Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation. Faseb J. 17 (2003) 944-946
51. Dervan A.G., Meshul C.K., Beales M., McBean G.J., Moore C., Totterdell S., Snyder A.K., and Meredith G.E. Astroglial plasticity and glutamate function in a chronic mouse model of Parkinson's disease. Exp. Neurol. 190 (2004) 145-156
52. Dibble L.E., Hale T.F., Marcus R.L., Droge J., Gerber J.P., and LaStayo P.C. High-intensity resistance training amplifies muscle hypertrophy and functional gains in persons with Parkinson's disease. Mov. Disord. 21 (2006) 1444-1452
53. Do Thi N.A., Saillour P., Ferrero L., Dedieu J.F., Mallet J., and Paunio T. Delivery of GDNF by an E1,E3/E4 deleted adenoviral vector and driven by a GFAP promoter prevents dopaminergic neuron degeneration in a rat model of Parkinson's disease. Gene Ther. 11 (2004) 746-756
54. Du Y., Ma Z., Lin S., Dodel R.C., Gao F., Bales K.R., Triarhou L.C., Chernet E., Perry K.W., Nelson D.L., Luecke S., Phebus L.A., Bymaster F.P., and Paul S.M. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 14669-14674
55. During M.J., Kaplitt Jr. M.G., Leone P., Xiao X., Elsworth J.D., Roth R.H., Sladek J.R., Redmond Jr. D.E., and O'Malley K.L. AAV-mediated transfer of tyrosine hydroxylase and aromatic amino acid decarboxylase genes into the primate brain: a direct gene therapy approach to Parkinson's disease. Soc Neurosci Abstr (1994), Society for Neuroscience, Miami Beach, Fl 1465
56. During M.J., Samulski R.J., Elsworth J.D., Kaplitt M.G., Leone P., Xiao X., Li J., Freese A., Taylor J.R., Roth R.H., Sladek Jr. J.R., O'Malley K.L., and Redmond Jr. D.E. In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector. Gene Ther. 5 (1998) 820-827
57. Elsworth J.D., and Roth R.H. Dopamine synthesis, uptake, metabolism, and receptors: relevance to gene therapy of Parkinson's disease. Exp. Neurol. 144 (1997) 4-9
58. Emadi S., Liu R., Yuan B., Schulz P., McAllister C., Lyubchenko Y., Messer A., and Sierks M.R. Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments. Biochemistry 43 (2004) 2871-2878
59. Ericson C., Georgievska B., and Lundberg C. Ex vivo gene delivery of GDNF using primary astrocytes transduced with a lentiviral vector provides neuroprotection in a rat model of Parkinson's disease. Eur. J. Neurosci. 22 (2005) 2755-2764
60. Esposito E., Di Matteo V., Benigno A., Pierucci M., Crescimanno G., and Di Giovanni G. Non-steroidal anti-inflammatory drugs in Parkinson's disease. Exp. Neurol. 205 (2007) 295-312
61. Evangelou E., Maraganore D.M., and Ioannidis J.P. Meta-analysis in genome-wide association datasets: strategies and application in Parkinson disease. PLoS ONE 2 (2007) e196
62. Faherty C.J., Raviie Shepherd K., Herasimtschuk A., and Smeyne R.J. Environmental enrichment in adulthood eliminates neuronal death in experimental Parkinsonism. Brain Res. Mol. Brain Res. 134 (2005) 170-179
63. Federoff H.J., and Mhyre T.R. Reversal of misfolding: prion disease behavioral and physiological impairments recover following postnatal neuronal deletion of the PrP gene. Neuron 53 (2007) 315-317
64. Fisher B.E., Petzinger G.M., Nixon K., Hogg E., Bremmer S., Meshul C.K., and Jakowec M.W. Exercise-induced behavioral recovery and neuroplasticity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse basal ganglia. J. Neurosci. Res. 77 (2004) 378-390
65. Fiszer U., Mix E., Fredrikson S., Kostulas V., Olsson T., and Link H. Gamma delta+ T cells are increased in patients with Parkinson's disease. J. Neurol. Sci. 121 (1994) 39-45
66. Fitoussi N., Sotnik-Barkai I., Tornatore C., Herzberg U., and Yadid G. Dopamine turnover and metabolism in the striatum of parkinsonian rats grafted with genetically-modified human astrocytes. Neuroscience 85 (1998) 405-413
67. Fored C.M., Fryzek J.P., Brandt L., Nise G., Sjogren B., McLaughlin J.K., Blot W.J., and Ekbom A. Parkinson's disease and other basal ganglia or movement disorders in a large nationwide cohort of Swedish welders. Occup. Environ. Med. 63 (2006) 135-140
68. Freed W.J., Geller H.M., Poltorak M., Cannon-Spoor H.E., Cottingham S.L., LaMarca M.E., Schultzberg M., Rehavi M., Paul S., and Ginns E.I. Genetically altered and defined cell lines for transplantation in animal models of Parkinson's disease. Prog. Brain Res. 82 (1990) 11-21
69. Gandhi S., Abou-Sleiman P.M., Healy D.G., Weale M., Gilks W., Ahmadi K., Goldstein D.B., and Wood N.W. Population genetic approaches to neurological disease: Parkinson's disease as an example. Philos. Trans. R. Soc. Lond., B. Biol. Sci. 360 (2005) 1573-1578
70. Geraerts M., Krylyshkina O., Debyser Z., and Baekelandt V. Concise review: therapeutic strategies for Parkinson disease based on the modulation of adult neurogenesis. Stem Cells 25 (2007) 263-270
71. Gerhard A., Pavese N., Hotton G., Turkheimer F., Es M., Hammers A., Eggert K., Oertel W., Banati R.B., and Brooks D.J. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol. Dis. 21 (2006) 404-412
72. Gorell J.M., Johnson C.C., Rybicki B.A., Peterson E.L., Kortsha G.X., Brown G.G., and Richardson R.J. Occupational exposures to metals as risk factors for Parkinson's disease. Neurology 48 (1997) 650-658
73. Gorell J.M., Johnson C.C., Rybicki B.A., Peterson E.L., Kortsha G.X., Brown G.G., and Richardson R.J. Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease. Neurotoxicology 20 (1999) 239-247
74. Gould E. How widespread is adult neurogenesis in mammals?. Nat. Rev., Neurosci. 8 (2007) 481-488
75. Greenamyre J.T., Betarbet R., Sherer T., and Panov A. Response: Parkinson's disease, pesticides and mitochondrial dysfunction. Trends Neurosci. 24 (2001) 247
76. Hakansson A., Westberg L., Nilsson S., Buervenich S., Carmine A., Holmberg B., Sydow O., Olson L., Johnels B., Eriksson E., and Nissbrandt H. Investigation of genes coding for inflammatory components in Parkinson's disease. Mov. Disord. 20 (2005) 569-573
77. Hancock D.B., Martin E.R., Stajich J.M., Jewett R., Stacy M.A., Scott B.L., Vance J.M., and Scott W.K. Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease. Arch. Neurol. 64 (2007) 576-580
78. Hellmann M.A., Panet H., Barhum Y., Melamed E., and Offen D. Increased survival and migration of engrafted mesenchymal bone marrow stem cells in 6-hydroxydopamine-lesioned rodents. Neurosci. Lett. 395 (2006) 124-128
79. Hernan M.A., Logroscino G., and Garcia Rodriguez L.A. Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease. Neurology 66 (2006) 1097-1099
80. Hida H., Hashimoto M., Fujimoto I., Nakajima K., Shimano Y., Nagatsu T., Mikoshiba K., and Nishino H. Dopa-producing astrocytes generated by adenoviral transduction of human tyrosine hydroxylase gene: in vitro study and transplantation to hemiparkinsonian model rats. Neurosci. Res. 35 (1999) 101-112
81. Hirsch E.C., Hunot S., and Hartmann A. Neuroinflammatory processes in Parkinson's disease. Parkinsonism Relat. Disord. 11 Suppl 1 (2005) S9-S15
82. Horellou P., Vigne E., Castel M.-N., Barneoud P., Colin P., Perricaudet M., Delaere P., and Mallet J. Direct intracerebral gene transfer of an adenoviral vector expressing tyrosine hydroxylase in a rat model of Parkinson's disease. Neuroreport 6 (1994) 49-53
83. Hsich G., Sena-Esteves M., and Breakefield X.O. Critical issues in gene therapy for neurologic disease. Hum. Gene Ther. 13 (2002) 579-604
84. Hurelbrink C.B., and Barker R.A. Prospects for the treatment of Parkinson's disease using neurotrophic factors. Expert Opin. Pharmacother. 2 (2001) 1531-1543
85. Hurelbrink C.B., and Barker R.A. The potential of GDNF as a treatment for Parkinson's disease. Exp. Neurol. 185 (2004) 1-6
86. Kamel F., Tanner C., Umbach D., Hoppin J., Alavanja M., Blair A., Comyns K., Goldman S., Korell M., Langston J., Ross G., and Sandler D. Pesticide exposure and self-reported Parkinson's disease in the agricultural health study. Am. J. Epidemiol. 165 (2007) 364-374
87. Kaplitt M.G., Leone P., Samulski R.J., Xiao X., Pfaff D.W., O'Malley K.L., and During M.J. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat. Genet. 8 (1994) 148-154
88. Kim J.M., Lee K.H., Jeon Y.J., Oh J.H., Jeong S.Y., Song I.S., Kim J.M., Lee D.S., and Kim N.S. Identification of genes related to Parkinson's disease using expressed sequence tags. DNA Res. 13 (2006) 275-286
89. Kim W.G., Mohney R.P., Wilson B., Jeohn G.H., Liu B., and Hong J.S. Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J. Neurosci. 20 (2000) 6309-6316
90. Klein R.L., Meyer E.M., Peel A.L., Zolotukhin S., Meyers C., Muzyczka N., and King M.A. Neuron-specific transduction in the rat septohippocampal or nigrostriatal pathway by recombinant adeno-associated virus vectors. Exp. Neurol. 150 (1998) 183-194
91. Klein R.L., Lewis M.H., Muzyczka N., and Meyer E.M. Prevention of 6-hydroxydopamine-induced rotational behavior by BDNF somatic gene transfer. Brain Res. 847 (1999) 314-320
92. Kluter H., Vieregge P., Stolze H., and Kirchner H. Defective production of interleukin-2 in patients with idiopathic Parkinson's disease. J. Neurol. Sci. 133 (1995) 134-139
93. Koeberle P.D., Gauldie J., and Ball A.K. Effects of adenoviral-mediated gene transfer of interleukin-10, interleukin-4, and transforming growth factor-beta on the survival of axotomized retinal ganglion cells. Neuroscience 125 (2004) 903-920
94. Kohutnicka M., Lewandowska E., Kurkowska-Jastrzebska I., Czlonkowski A., and Czlonkowska A. Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Immunopharmacology 39 (1998) 167-180
95. Kokovay E., and Cunningham L.A. Bone marrow-derived microglia contribute to the neuroinflammatory response and express iNOS in the MPTP mouse model of Parkinson's disease. Neurobiol. Dis. 19 (2005) 471-478
96. Kordower J.H., Bloch J., Ma S.Y., Chu Y., Palfi S., Roitberg B.Z., Emborg M., Hantraye P., Deglon N., and Aebischer P. Lentiviral gene transfer to the nonhuman primate brain. Exp. Neurol. 160 (1999) 1-16
97. Kordower J.H., Emborg M.E., Bloch J., Ma S.Y., Chu Y., Leventhal L., McBride J., Chen E.Y., Palfi S., Roitberg B.Z., Brown W.D., Holden J.E., Pyzalski R., Taylor M.D., Carvey P., Ling Z., Trono D., Hantraye P., Deglon N., and Aebischer P. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290 (2000) 767-773
98. Kordower J.H. In vivo gene delivery of glial cell line-derived neurotrophic factor for Parkinson's disease. Ann. Neurol. 53 Suppl 3 (2003) S120-S132 discussion S132-124
99. Laburthe M., and Couvineau A. Molecular pharmacology and structure of VPAC Receptors for VIP and PACAP. Regul. Pept. 108 (2002) 165-173
100. Langston J.W., Ballard P., Tetrud J.W., and Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219 (1983) 979-980
101. Langston J.W., Irwin I., Langston E.B., and Forno L.S. 1-Methyl-4-phenylpyridinium ion (MPP+): identification of a metabolite of MPTP, a toxin selective to the substantia nigra. Neurosci. Lett. 48 (1984) 87-92
102. Langston J.W., Forno L.S., Tetrud J., Reeves A.G., Kaplan J.A., and Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann. Neurol. 46 (1999) 598-605
103. Lawson L.J., Perry V.H., Dri P., and Gordon S. Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 39 (1990) 151-170
104. Leblhuber F., Neurauter G., and Fuchs D. Oxidative damage and cytogenic analysis in leukocytes of Parkinson's disease patients. Neurology 60 (2003) 729 (author reply 729)
105. Lecerf J.M., Shirley T.L., Zhu Q., Kazantsev A., Amersdorfer P., Housman D.E., Messer A., and Huston J.S. Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 4764-4769
106. Ling Z., Gayle D.A., Ma S.Y., Lipton J.W., Tong C.W., Hong J.S., and Carvey P.M. In utero bacterial endotoxin exposure causes loss of tyrosine hydroxylase neurons in the postnatal rat midbrain. Mov. Disord. 17 (2002) 116-124
107. Litvan I., Chesselet M.F., Gasser T., Di Monte D.A., Parker Jr. D., Hagg T., Hardy J., Jenner P., Myers R.H., Price D., Hallett M., Langston W.J., Lang A.E., Halliday G., Rocca W., Duyckaerts C., Dickson D.W., Ben-Shlomo Y., Goetz C.G., and Melamed E. The etiopathogenesis of Parkinson disease and suggestions for future research. Part II. J. Neuropathol. Exp. Neurol. 66 (2007) 329-336
108. Logroscino G. The role of early life environmental risk factors in Parkinson disease: what is the evidence?. Environ. Health Perspect. 113 (2005) 1234-1238
109. Lundberg C., Horellou P., Mallet J., and Bjorklund A. Generation of DOPA-producing astrocytes by retroviral transduction of the human tyrosine hydroxylase gene: in vitro characterization and in vivo effects in the rat Parkinson model. Exp. Neurol. 139 (1996) 39-53
110. Luo Y., Henricksen L.A., Giuliano R.E., Prifti L., Callahan L.M., and Federoff H.J. VIP is a transcriptional target of Nurr1 in dopaminergic cells. Exp. Neurol. 203 (2007) 221-232
111. Lynch W.P., Sharpe A.H., and Snyder E.Y. Neural stem cells as engraftable packaging lines can mediate gene delivery to microglia: evidence from studying retroviral env-related neurodegeneration. J. Virol. 73 (1999) 6841-6851
112. Maguire-Zeiss K.A., and Federoff H.J. Convergent pathobiologic model of Parkinson's disease. Ann. N. Y. Acad. Sci. 991 (2003) 152-166
113. Maguire-Zeiss K.A., and Federoff H.J. Novel gene therapeutic strategies for neurodegenerative diseases. Ernst Schering Res. Found. Workshop (2005) 147-171
114. Maguire-Zeiss K.A., Wang C.I., Yehling E., Sullivan M.A., Short D.W., Su X., Gouzer G., Henricksen L.A., Wuertzer C.A., and Federoff H.J. Identification of human alpha-synuclein specific single chain antibodies. Biochem. Biophys. Res. Commun. 349 (2006) 1198-1205
115. Mandel R.J., Rendahl K.G., Spratt S.K., Snyder R.O., Cohen L.K., and Leff S.E. Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson's disease. J. Neurosci. 18 (1998) 4271-4284
116. Manning-Bog A.B., McCormack A.L., Li J., Uversky V.N., Fink A.L., and Di Monte D.A. The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J. Biol. Chem. 277 (2002) 1641-1644
117. Maraganore D.M., de Andrade M., Lesnick T.G., Strain K.J., Farrer M.J., Rocca W.A., Pant P.V., Frazer K.A., Cox D.R., and Ballinger D.G. High-resolution whole-genome association study of Parkinson disease. Am. J. Hum. Genet. 77 (2005) 685-693
118. Marsh G.M., and Gula M.J. Employment as a welder and Parkinson disease among heavy equipment manufacturing workers. J. Occup. Environ. Med. 48 (2006) 1031-1046
119. Mattson M.P., Duan W., Wan R., and Guo Z. Prophylactic activation of neuroprotective stress response pathways by dietary and behavioral manipulations. NeuroRx 1 (2004) 111-116
120. McCormack A.L., Thiruchelvam M., Manning-Bog A.B., Thiffault C., Langston J.W., Cory-Slechta D.A., and Di Monte D.A. Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol. Dis. 10 (2002) 119-127
121. McGeer E.G., Klegeris A., and McGeer P.L. Inflammation, the complement system and the diseases of aging. Neurobiol. Aging 26 Suppl 1 (2005) 94-97
122. McGeer P.L., Itagaki S., Boyes B.E., and McGeer E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38 (1988) 1285-1291
123. McGeer P.L., and McGeer E.G. Inflammation and the degenerative diseases of aging. Ann. N. Y. Acad. Sci. 1035 (2004) 104-116
124. Messer A., and McLear J. The therapeutic potential of intrabodies in neurologic disorders: focus on huntington and Parkinson diseases. BioDrugs 20 (2006) 327-333
125. Migliore L., Scarpato R., Coppede F., Petrozzi L., Bonuccelli U., and Rodilla V. Chromosome and oxidative damage biomarkers in lymphocytes of Parkinson's disease patients. Int. J. Hyg. Environ. Health 204 (2001) 61-66
126. Migliore L., Petrozzi L., Lucetti C., Gambaccini G., Bernardini S., Scarpato R., Trippi F., Barale R., Frenzilli G., Rodilla V., and Bonuccelli U. Oxidative damage and cytogenetic analysis in leukocytes of Parkinson's disease patients. Neurology 58 (2002) 1809-1815
127. Miller R.M., Ogihara M., and Federoff H.J. Analysis of gene expression profiles in the injured nigrostriatal pathway. The 31st Annual Meeting of the Society for Neuroscience (2001), Society for Neuroscience, San Diego, CA
128. Miller R.M., Callahan L.M., Casaceli C., Chen L., Kiser G.L., Chui B., Kaysser-Kranich T.M., Sendera T.J., Palaniappan C., and Federoff H.J. Dysregulation of gene expression in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse substantia nigra. J. Neurosci. 24 (2004) 7445-7454
129. Miller R.M., and Federoff H.J. Altered gene expression profiles reveal similarities and differences between Parkinson disease and model systems. Neuroscientist 11 (2005) 539-549
130. Miller R.M., and Federoff H.J. Microarrays in Parkinson's disease: a systematic approach. NeuroRx 3 (2006) 319-326
131. Miller R.M., Kiser G.L., Kaysser-Kranich T.M., Lockner R.J., Palaniappan C., and Federoff H.J. Robust dysregulation of gene expression in substantia nigra and striatum in Parkinson's disease. Neurobiol. Dis. 21 (2006) 305-313
132. Miller R.M., Kiser G.L., Kaysser-Kranich T., Casaceli C., Colla E., Lee M.K., Palaniappan C., and Federoff H.J. Wild-type and mutant alpha-synuclein induce a multi-component gene expression profile consistent with shared pathophysiology in different transgenic mouse models of PD. Exp. Neurol. 204 (2007) 421-432
133. Miller T.W., and Messer A. Intrabody applications in neurological disorders: progress and future prospects. Mol. Ther. 12 (2005) 394-401
134. Miller T.W., Zhou C., Gines S., MacDonald M.E., Mazarakis N.D., Bates G.P., Huston J.S., and Messer A. A human single-chain Fv intrabody preferentially targets amino-terminal Huntington's fragments in striatal models of Huntington's disease. Neurobiol. Dis. 19 (2005) 47-56
135. Mirza B., Hadberg H., Thomsen P., and Moos T. The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease. Neuroscience 95 (2000) 425-432
136. Mochizuki H., and Mizuno Y. Gene therapy for Parkinson's disease. J. Neural. Transm., Suppl. (2003) 205-213
137. Morelli A.E., Larregina A.T., Smith-Arica J., Dewey R.A., Southgate T.D., Ambar B., Fontana A., Castro M.G., and Lowenstein P.R. Neuronal and glial cell type-specific promoters within adenovirus recombinants restrict the expression of the apoptosis-inducing molecule Fas ligand to predetermined brain cell types, and abolish peripheral liver toxicity. J. Gen. Virol. 80 (1999) 571-583
138. Nakano K., Migita M., Mochizuki H., and Shimada T. Differentiation of transplanted bone marrow cells in the adult mouse brain. Transplantation 71 (2001) 1735-1740
139. Neumann H. Microglia: a cellular vehicle for CNS gene therapy. J. Clin. Invest. 116 (2006) 2857-2860
140. Offen D., Sherki Y., Melamed E., Fridkin M., Brenneman D.E., and Gozes I. Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease. Brain Res. 854 (2000) 257-262
141. Olanow C.W. Manganese-induced parkinsonism and Parkinson's disease. Ann. N. Y. Acad. Sci. 1012 (2004) 209-223
142. Oransky I. Gene therapy trial for Parkinson's disease begins. Lancet 362 (2003) 712
143. Paisan-Ruiz C., Jain S., Evans E.W., Gilks W.P., Simon J., van der Brug M., Lopez de Munain A., Aparicio S., Gil A.M., Khan N., Johnson J., Martinez J.R., Nicholl D., Carrera I.M., Pena A.S., de Silva R., Lees A., Marti-Masso J.F., Perez-Tur J., Wood N.W., and Singleton A.B. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44 (2004) 595-600
144. Papadakis E.D., Nicklin S.A., Baker A.H., and White S.J. Promoters and control elements: designing expression cassettes for gene therapy. Curr. Gene Ther. 4 (2004) 89-113
145. Parkinson J. An Essay on the Shaking Palsy (1817), Sherwood, Neely, and Jones, Paternoster Row, London
146. Pellegatta S., Tunici P., Poliani P.L., Dolcetta D., Cajola L., Colombelli C., Ciusani E., Di Donato S., and Finocchiaro G. The therapeutic potential of neural stem/progenitor cells in murine globoid cell leukodystrophy is conditioned by macrophage/microglia activation. Neurobiol. Dis. 21 (2006) 314-323
147. Peluffo H., Aris A., Acarin L., Gonzalez B., Villaverde A., and Castellano B. Nonviral gene delivery to the central nervous system based on a novel integrin-targeting multifunctional protein. Hum. Gene Ther. 14 (2003) 1215-1223
148. Pestka S., Krause C.D., Sarkar D., Walter M.R., Shi Y., and Fisher P.B. Interleukin-10 and related cytokines and receptors. Annu. Rev. Immunol. 22 (2004) 929-979
149. Petzinger G.M., Walsh J.P., Akopian G., Hogg E., Abernathy A., Arevalo P., Turnquist P., Vuckovic M., Fisher B.E., Togasaki D.M., and Jakowec M.W. Effects of treadmill exercise on dopaminergic transmission in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury. J. Neurosci. 27 (2007) 5291-5300
150. Polymeropoulos M.H., Higgins J.J., Golbe L.I., Johnson W.G., Ide S.E., Di Iorio G., Sanges G., Stenroos E.S., Pho L.T., Schaffer A.A., Lazzarini A.M., Nussbaum R.L., and Duvoisin R.C. Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science 274 (1996) 1197-1199
151. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., and Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 (1997) 2045-2047
152. Polymeropoulos M.H. Genetics of Parkinson's disease. Ann. N. Y. Acad. Sci. 920 (2000) 28-32
153. Priller J., Flugel A., Wehner T., Boentert M., Haas C.A., Prinz M., Fernandez-Klett F., Prass K., Bechmann I., de Boer B.A., Frotscher M., Kreutzberg G.W., Persons D.A., and Dirnagl U. Targeting gene-modified hematopoietic cells to the central nervous system: use of green fluorescent protein uncovers microglial engraftment. Nat. Med. 7 (2001) 1356-1361
154. Priller J., Prinz M., Heikenwalder M., Zeller N., Schwarz P., Heppner F.L., and Aguzzi A. Early and rapid engraftment of bone marrow-derived microglia in scrapie. J. Neurosci. 26 (2006) 11753--11762
155. Priyadarshi A., Khuder S.A., Schaub E.A., and Priyadarshi S.S. Environmental risk factors and Parkinson's disease: a metaanalysis. Environ. Res. 86 (2001) 122-127
156. Purisai M.G., McCormack A.L., Cumine S., Li J., Isla M.Z., and Di Monte D.A. Microglial activation as a priming event leading to paraquat-induced dopaminergic cell degeneration. Neurobiol. Dis. 25 (2007) 392-400
157. Qian L., Block M.L., Wei S.J., Lin C.F., Reece J., Pang H., Wilson B., Hong J.S., and Flood P.M. Interleukin-10 protects lipopolysaccharide-induced neurotoxicity in primary midbrain cultures by inhibiting the function of NADPH oxidase. J. Pharmacol. Exp. Ther. 319 (2006) 44-52
158. Qian L., Hong J.S., and Flood P.M. Role of microglia in inflammation-mediated degeneration of dopaminergic neurons: neuroprotective effect of interleukin 10. J. Neural. Transm., Suppl. (2006) 367-371
159. Racette B.A., McGee-Minnich L., Moerlein S.M., Mink J.W., Videen T.O., and Perlmutter J.S. Welding-related parkinsonism: clinical features, treatment, and pathophysiology. Neurology 56 (2001) 8-13
160. Raoul C., Barker S.D., and Aebischer P. Viral-based modelling and correction of neurodegenerative diseases by RNA interference. Gene Ther. 13 (2006) 487-495
161. Raymon H.K., Thode S., and Gage F.H. Application of ex vivo gene therapy in the treatment of Parkinson's disease. Exp. Neurol. 144 (1997) 82-91
162. Reglodi D., Lubics A., Tamas A., Szalontay L., and Lengvari I. Pituitary adenylate cyclase activating polypeptide protects dopaminergic neurons and improves behavioral deficits in a rat model of Parkinson's disease. Behav. Brain Res. 151 (2004) 303-312
163. Reuter I., Engelhardt M., Stecker K., and Baas H. Therapeutic value of exercise training in Parkinson's disease. Med. Sci. Sports Exerc. 31 (1999) 1544-1549
164. Richfield E.K., Thiruchelvam M.J., Cory-Slechta D.A., Wuertzer C., Gainetdinov R.R., Caron M.G., Di Monte D.A., and Federoff H.J. Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice. Exp. Neurol. 175 (2002) 35-48
165. Sadek A.H., Rauch R., and Schulz P.E. Parkinsonism due to manganism in a welder. Int. J. Toxicol. 22 (2003) 393-401
166. Sapru M.K., Yates J.W., Hogan S., Jiang L., Halter J., and Bohn M.C. Silencing of human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi. Exp. Neurol. 198 (2006) 382-390
167. Sawada M., Imai F., Suzuki H., Hayakawa M., Kanno T., and Nagatsu T. Brain-specific gene expression by immortalized microglial cell-mediated gene transfer in the mammalian brain. FEBS Lett. 433 (1998) 37-40
168. Scherzer C.R., Eklund A.C., Morse L.J., Liao Z., Locascio J.J., Fefer D., Schwarzschild M.A., Schlossmacher M.G., Hauser M.A., Vance J.M., Sudarsky L.R., Standaert D.G., Growdon J.H., Jensen R.V., and Gullans S.R. Molecular markers of early Parkinson's disease based on gene expression in blood. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 955-960
169. Segovia J., Vergara P., and Brenner M. Astrocyte-specific expression of tyrosine hydroxylase after intracerebral gene transfer induces behavioral recovery in experimental parkinsonism. Gene Ther. 5 (1998) 1650-1655
170. Shan X., Chi L., Bishop M., Luo C., Lien L., Zhang Z., and Liu R. Enhanced de novo neurogenesis and dopaminergic neurogenesis in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease-like mice. Stem Cells 24 (2006) 1280-1287
171. Shen Y., Muramatsu S.I., Ikeguchi K., Fujimoto K.I., Fan D.S., Ogawa M., Mizukami H., Urabe M., Kume A., Nagatsu I., Urano F., Suzuki T., Ichinose H., Nagatsu T., Monahan J., Nakano I., and Ozawa K. Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-l-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease. Hum. Gene Ther. 11 (2000) 1509-1519
172. Shinotoh H. Neuroimaging of PD, PSP, CBD and MSA-PET and SPECT studies. J. Neurol. 253 Suppl 3 (2006) iii30-iii34
173. Singleton A., Gwinn-Hardy K., Sharabi Y., Li S.T., Holmes C., Dendi R., Hardy J., Crawley A., and Goldstein D.S. Association between cardiac denervation and parkinsonism caused by alpha-synuclein gene triplication. Brain 127 (2004) 768-772
174. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., Hulihan M., Peuralinna T., Dutra A., Nussbaum R., Lincoln S., Crawley A., Hanson M., Maraganore D., Adler C., Cookson M.R., Muenter M., Baptista M., Miller D., Blancato J., Hardy J., and Gwinn-Hardy K. Alpha-synuclein locus triplication causes Parkinson's disease. Science 302 (2003) 841
175. Sortwell C.E., Bowers W.J., Counts S.E., Pitzer M.R., Fleming M.F., McGuire S.O., Maguire-Zeiss K.A., Federoff H.J., and Collier T.J. Effects of ex vivo transduction of mesencephalic reaggregates with bcl-2 on grafted dopamine neuron survival. Brain Res. 1134 (2007) 33-44
176. Steiner B., Winter C., Hosman K., Siebert E., Kempermann G., Petrus D.S., and Kupsch A. Enriched environment induces cellular plasticity in the adult substantia nigra and improves motor behavior function in the 6-OHDA rat model of Parkinson's disease. Exp. Neurol. 199 (2006) 291-300
177. Steingart R.A., Solomon B., Brenneman D.E., Fridkin M., and Gozes I. VIP and peptides related to activity-dependent neurotrophic factor protect PC12 cells against oxidative stress. J. Mol. Neurosci. 15 (2000) 137-145
178. Strayer D.S., Agrawal L., Cordelier P., Liu B., Louboutin J.P., Marusich E., McKee H.J., Ren C.N., and Strayer M.S. Long-term gene expression in dividing and nondividing cells using SV40-derived vectors. Mol. Biotechnol. 34 (2006) 257-270
179. Su X., Maguire-Zeiss K.A., Giuliano R., Prifti L., Venkatesh K., and Federoff H.J. Synuclein activates microglia in a model of Parkinson's disease. Neurobiol. Aging (2007) (Epub ahead of print; PMID 17537546)
180. Sugama S., Yang L., Cho B.P., DeGiorgio L.A., Lorenzl S., Albers D.S., Beal M.F., Volpe B.T., and Joh T.H. Age-related microglial activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL/6 mice. Brain Res. 964 (2003) 288-294
181. Tanaka S., and Lieben J. Manganese poisoning and exposure in Pennsylvania. Arch. Environ. Health 19 (1969) 674-684
182. Tande D., Hoglinger G., Debeir T., Freundlieb N., Hirsch E.C., and Francois C. New striatal dopamine neurons in MPTP-treated macaques result from a phenotypic shift and not neurogenesis. Brain 129 (2006) 1194-1200
183. Tanner C.M., and Marder K. Movement disorders. In: Nelson L.M., Tanner C.M., Van Den Eden S., and McGuire V.M. (Eds). Neuroepidemiology: From Principles to Practice (2003), Oxford University Press, New York 131-161
184. Thiruchelvam M., Brockel B.J., Richfield E.K., Baggs R.B., and Cory-Slechta D.A. Potentiated and preferential effects of combined paraquat and maneb on nigrostriatal dopamine systems: environmental risk factors for Parkinson's disease?. Brain Res. 873 (2000) 225-234
185. Thiruchelvam M., Richfield E.K., Baggs R.B., Tank A.W., and Cory-Slechta D.A. The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson's disease. J. Neurosci. 20 (2000) 9207-9214
186. Tillerson J.L., Caudle W.M., Reveron M.E., and Miller G.W. Exercise induces behavioral recovery and attenuates neurochemical deficits in rodent models of Parkinson's disease. Neuroscience 119 (2003) 899-911
187. Ton T.G., Heckbert S.R., Longstreth Jr. W.T., Rossing M.A., Kukull W.A., Franklin G.M., Swanson P.D., Smith-Weller T., and Checkoway H. Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease. Mov. Disord. 21 (2006) 964-969
188. Tsuji D., Kuroki A., Ishibashi Y., Itakura T., and Itoh K. Metabolic correction in microglia derived from Sandhoff disease model mice. J. Neurochem. 94 (2005) 1631-1638
189. Tuncel N., Sener E., Cerit C., Karasu U., Gurer F., Sahinturk V., Baycu C., Ak D., and Filiz Z. Brain mast cells and therapeutic potential of vasoactive intestinal peptide in a Parkinson's disease model in rats: brain microdialysis, behavior, and microscopy. Peptides 26 (2005) 827-836
190. Urakawa S., Hida H., Masuda T., Misumi S., Kim T.S., and Nishino H. Environmental enrichment brings a beneficial effect on beam walking and enhances the migration of doublecortin-positive cells following striatal lesions in rats. Neuroscience 144 (2007) 920-933
191. Valente E.M., Bentivoglio A.R., Dixon P.H., Ferraris A., Ialongo T., Frontali M., Albanese A., and Wood N.W. Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36. Am. J. Hum. Genet. 68 (2001) 895-900
192. Valente E.M., Abou-Sleiman P.M., Caputo V., Muqit M.M., Harvey K., Gispert S., Ali Z., Del Turco D., Bentivoglio A.R., Healy D.G., Albanese A., Nussbaum R., Gonzalez-Maldonado R., Deller T., Salvi S., Cortelli P., Gilks W.P., Latchman D.S., Harvey R.J., Dallapiccola B., Auburger G., and Wood N.W. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304 (2004) 1158-1160
193. Vilaboa N., and Voellmy R. Regulatable gene expression systems for gene therapy. Curr. Gene Ther. 6 (2006) 421-438
194. Wang C.Y., and Wang S. Astrocytic expression of transgene in the rat brain mediated by baculovirus vectors containing an astrocyte-specific promoter. Gene Ther. 13 (2006) 1447-1456
195. Wang G., Qi C., Fan G.H., Zhou H.Y., and Chen S.D. PACAP protects neuronal differentiated PC12 cells against the neurotoxicity induced by a mitochondrial complex I inhibitor, rotenone. FEBS Lett. 579 (2005) 4005-4011
196. Weber W., and Fussenegger M. Pharmacologic transgene control systems for gene therapy. J. Gene Med. 8 (2006) 535-556
197. Weiler J., Hunziker J., and Hall J. Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease?. Gene Ther. 13 (2006) 496-502
198. Whitlock Jr. C.M., Amuso S.J., and Bittenbender J.B. Chronic neurological disease in two manganese steel workers. Am. Ind. Hyg. Assoc. J. 27 (1966) 454-459
199. Whitton P.S. Inflammation as a causative factor in the aetiology of Parkinson's disease. Br. J. Pharmacol. 150 (2007) 963-976
200. Wolfgang W.J., Miller T.W., Webster J.M., Huston J.S., Thompson L.M., Marsh J.L., and Messer A. Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 11563-11568
201. Wu D.C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., Choi D.K., Ischiropoulos H., and Przedborski S. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 22 (2002) 1763-1771
202. Wu Y.R., Feng I.H., Lyu R.K., Chang K.H., Lin Y.Y., Chan H., Hu F.J., Lee-Chen G.J., and Chen C.M. Tumor necrosis factor-alpha promoter polymorphism is associated with the risk of Parkinson's disease. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 144 (2007) 300-304
203. Yamada M., Oligino T., Mata M., Goss J.R., Glorioso J.C., and Fink D.J. Herpes simplex virus vector-mediated expression of Bcl-2 prevents 6-hydroxydopamine-induced degeneration of neurons in the substantia nigra in vivo. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 4078-4083
204. Ye M., Wang X.J., Zhang Y.H., Lu G.Q., Liang L., Xu J.Y., and Chen S.D. Transplantation of bone marrow stromal cells containing the neurturin gene in rat model of Parkinson's disease. Brain Res. 1142 (2007) 206-216
205. Ye M., Wang X.J., Zhang Y.H., Lu G.Q., Liang L., Xu J.Y., and Sheng-Di C. Therapeutic effects of differentiated bone marrow stromal cell transplantation on rat models of Parkinson's disease. Parkinsonism Relat. Disord. 13 (2007) 44-49
206. Yen L., Svendsen J., Lee J.S., Gray J.T., Magnier M., Baba T., D'Amato R.J., and Mulligan R.C. Exogenous control of mammalian gene expression through modulation of RNA self-cleavage. Nature 431 (2004) 471-476
207. Yoshimi K., Ren Y.R., Seki T., Yamada M., Ooizumi H., Onodera M., Saito Y., Murayama S., Okano H., Mizuno Y., and Mochizuki H. Possibility for neurogenesis in substantia nigra of parkinsonian brain. Ann. Neurol. 58 (2005) 31-40
208. Yoshimoto Y., Lin Q., Collier T.J., Frim D.M., Breakefield X.O., and Bohn M.C. Astrocytes retrovirally transduced with BDNF elicit behavioral improvement in a rat model of Parkinson's disease. Brain Res. 691 (1995) 25-36
209. Zarranz J.J., Alegre J., Gomez-Esteban J.C., Lezcano E., Ros R., Ampuero I., Vidal L., Hoenicka J., Rodriguez O., Atares B., Llorens V., Gomez Tortosa E., del Ser T., Munoz D.G., and de Yebenes J.G. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55 (2004) 164-173
210. Zhao M., Momma S., Delfani K., Carlen M., Cassidy R.M., Johansson C.B., Brismar H., Shupliakov O., Frisen J., and Janson A.M. Evidence for neurogenesis in the adult mammalian substantia nigra. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 7925-7930
211. Zhou C., Emadi S., Sierks M.R., and Messer A. A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein. Mol. Ther. 10 (2004) 1023-1031
212. Zimprich A., Biskup S., Leitner P., Lichtner P., Farrer M., Lincoln S., Kachergus J., Hulihan M., Uitti R.J., Calne D.B., Stoessl A.J., Pfeiffer R.F., Patenge N., Carbajal I.C., Vieregge P., Asmus F., Muller-Myhsok B., Dickson D.W., Meitinger T., Strom T.M., Wszolek Z.K., and Gasser T. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44 (2004) 601-607